Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for f8 protein, human (compound)


DrugBank
Identification
Name: F8 protein, human
Name (isomeric): DB00025
Drug Type: biotech
Synonyms:
Coagulation factor VIII precursor; Procoagulant component; AHF
Brand: Hemofil M, Helixate FS, Advate, Alphanate, Monoclate-P, Xyntha, Kogenate, Humate-P, ReFacto, Helixate, Monarc-M, Koate-HP, Kogenate FS, Bioclate, Hyate:C
Category: Coagulants, Thrombotic Agents
Pharmacology
Indication: For the treatment of hemophilia A, von Willebrand diseae and Factor XIII deficiency
Pharmacology: Antihemophilic Factor binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of Action: Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).
Half Life: 8.4-19.3 hrs
Clearance: 4.1 mL/h•kg [Previously treated pediatric patients]
Affected organisms: Humans and other mammals

Targets


Enzymes